

2nd Meeting

European Myeloma Network

The logo for the European Myeloma Network (EMN) features the letters "EMN" in a bold, white, sans-serif font. A stylized orange arrow points from the left towards the "E".

Program

Virtual | March 3-6, 2021

WEDNESDAY, MARCH 3, 2021

13.45-14.00 **OPENING CEREMONY**

14.00-14.45 **FROM MGUS TO SMM TO MM:
FROM BENCH TO BEDSIDE**

Chairmen: S. Kristinsson, S. Lonial

The role of the immunomicroenvironment in evolving
myeloma precursor states - **N. Bolli**

The biology and treatment of MGUS of clinical significance - **M.C. Minnema**

SMM: what is it and how to treat? - **S. Lonial**

15.00-16.00 **CELGENE - A BRISTOL MEYERS SQUIBB COMPANY
SPONSORED SYMPOSIUM**

Harnessing the Immune System in Multiple Myeloma

Chair: N. van de Donk

Introduction: the importance of the immune microenvironment
in multiple myeloma - **N. van de Donk**

Broad immune stimulation in myeloma: the role of cereblon modulator - **F. Davies**

Targeted immune stimulation in myeloma: immunotherapies - **M.V. Mateos**

Targeted immune stimulation in Myeloma: cellular Therapies - **N. Raje**

Discussion

16.15-17.00 **FROM BENCH TO BEDSIDE SESSION
GENOMICS IN MM**

Chairmen: B. Paiva, P. Sonneveld

Short introduction of an expert in the field setting the stage - **P. Sonneveld**

What is high risk disease? - **M. Kaiser**

Are we ready to make a change in the treatment of high risk disease? - **C. Pawlyn**

17.15-18.15 **AMGEN SPONSORED SYMPOSIUM
The cycle of evolution in multiple myeloma management
what's around the next corner?**

Chair: K. Weisel

Introduction - **K. Weisel**

Guiding the way - Is it time for biomarker - driven treatment in myeloma? - **M. Kaiser**

At the crossroads – Retreat or switch? - **K. Weisel**

A steep incline – Cumulative toxicities in myeloma treatment - **H. Ludwig**

Discussion

18.30-19.15 **RESPONSE MONITORING IN MULTIPLE MYELOMA**

Chairmen: H. Ludwig, B. Paiva

M-protein detection; a matter of mass or velocity? - **D. Murray**

MRD detection - how, when and what then? - **B. Paiva**

Shedding light by PET-scans? - **E. Zamagni**

THURSDAY, MARCH 4, 2021

14.00-15.00 **ELDERLY PATIENTS WITH MYELOMA**

Chairmen: M. Boccadoro, S. Zweegman

Short introduction by an expert in the field to set the stage - **S. Zweegman**

How to treat fit non-Tx eligible patients? - **M. Boccadoro**

How to treat unfit and frail patients - **A. Larocca**

Novel trial designs based on aging instead of age? - **G. Cook**

15.15-16.15 **YOUNG PATIENTS WITH MYELOMA**

Chairmen: P. Moreau, P. Sonneveld

Short introduction by an expert in the field to set the stage - **M. Cavo**

First line treatment - **F. Gay**

To maintain or not and how? - **G. Jackson**

Optimal treatment sequences at relapse - **P. Moreau**

16.30-17.30 **JANSSEN SPONSORED SYMPOSIUM**

Managing patients with MM, now and in the new normal

Chairmen: M.V. Mateos, S. Zweegman

Welcome and introduction - **S. Zweegman**

Advances in NDMM management - **S. Zweegman**

Panel discussion: How to translate this data into clinical practice now?

F. Gay, P. Rodríguez Otero

Novel agents in R/R MM management - **M.V. Mateos**

Panel discussion: How to translate this data into clinical practice in the new normal

F. Gay, P. Rodríguez Otero

17.45-18.30 **SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA**

Chairmen: E. Kastritis, S. Treon

Biology of the disease - from genotype to phenotype? - **S. Treon**

Treatment in front line - **E. Kastritis**

Treatment at relapse - **M.J. Kersten**

18.45-19.15 **PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALK**

Chairman: B. Durie

IMF - USA - **B. Durie**

MPE - Myeloma patient groups across Europe - **H. Schreurs**

FRIDAY, MARCH 5, 2021

12.45-13.45 MEET THE EXPERT

- Management of MM patients from a nurse's perspective
A. Bernardini, C. Eeltink
- Aggressive disease in daily practice - **A. Broijl, K. Weisel**
- RRMM in daily practice - **C. Driessen, H. Goldschmidt**

14.00-14.30 FROM BENCH TO BEDSIDE SESSION - MOVING OUT OF THE MARROW

Chairmen: **F. Gay, M. Kaiser**

Plasma cell leukemia - different biology, different treatment? - **S. Usmani**
Does extramedullary means extra treatment? - **X. Leleu**

14.45-15.30 SPECIAL CONDITIONS AL AMYLOIDOSIS & LIGHT CHAIN DEPOSITION DISEASE

Chairmen: **E. Kastiris, G. Palladini**

AL Amyloidosis: mechanisms of disease and biomarkers - **G. Palladini**
Early diagnosis and optimal treatment - **P. Milani**
Diagnosis and management of light chain deposition disease - **F. Bridoux**

15.45-16.45 SANOFI SPONSORED SYMPOSIUM Management of relapsed and refractory multiple myeloma with novel monoclonal antibody-based regimens: from evidence based considerations to clinical practice

Chairmen: **P. Moreau, P. Sonneveld**

Welcome and introduction - **P. Moreau**

Mechanisms of actions of CD38 monoclonal antibodies - **N. Von de Donk**

Optimization of the treatment sequence with available treatments

in lenalidomide refractory multiple myeloma patients – Level of evidence - **E. Ocio**

AntiCD38 monoclonal antibody therapy in combinations with
pomalidomide and dexamethasone – Level of evidence - **X. Leleu**

Discussion and closing remarks

17.00-18.00 DEBATE SESSION

Chairmen: **F. Davies, M. Mohty**

Should all elderly receive daratumumab in first line? - YES - **M.V. Mateos** vs NO - **S. Zweegman**

Switch induction or go directly to transplant in case of suboptimal response?

F. Schjesvold (directly to transplantation) vs **R. Hajek** (switch induction)

Do all MGUS patients need follow-up? - YES - **S. Kristinsson** vs NO - **J. Bladé**

18.15-19.00 SPECIAL ATTENTION TO

Chairmen: **H. Ludwig, I. Nijhof**

Bone disease - **E. Terpos**

Cytokine release syndrome and neurologic symptoms with novel immune therapy - **N. Raje**

From bacteria to viruses - **M. Delforge**

SATURDAY, MARCH 6, 2021

12.45-13.45 MEET THE EXPERT

SMM to treat or not - **A. Broijl, S. Lonial**

Frail patients in daily practice - **A. Larocca, I. Nijhof**

10.50-11.50 SPONSORED LECTURES

Chairmen: **M. Boccadoro, G. Cook**

- **ADAPTIVE:** Application of Immunosequencing for MRD Determination - **L. Kirsch**
- **GSK:** Recent advances in approved and investigational agents targeting B-cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (RRMM) - **R. Popat**
- **TAKEDA:** Oral Proteasome Inhibitor Maintenance in Non-transplant Newly Diagnosed Multiple Myeloma: Results and Subanalyses of the TOURMALINE-MM4 Study - **E. Terpos**

11.50-12.50 JOINT EMN-EHA SYMPOSIUM

Chairmen: **N. van de Donk, M.V. Mateos**

Immune therapy from rationale to treatment - **P. Sonneveld**

Current evidence for bispecifics in MM treatment - **H. Einsele**

Current evidence for CARt cells in MM treatment - **P. Rodriguez-Otero**

16.15-17.15 BEST ABSTRACTS - ORAL PRESENTATIONS

Chairmen: **C. Driessen, M. Raab, F. Schjesvold, K. Weisel**

17.30-18.15 FROM BENCH TO BEDSIDE SESSION - IMMUNESYSTEM IN MM

Chairmen: **M. O'Dwyer, T. Plesner**

Short introduction of an expert in the field setting the stage - **T. Plesner**

The biology of immune resistance in MM - **L. Rasche**

How to overcome immune resistance in MM - **N. van de Donk**

18.30-19.15 FROM BENCH TO BEDSIDE SESSION FROM THE MICROENVIRONMENT TO OVERCOMING DRUG RESISTANCE

Chairmen: **E. Menu, E. Ocio**

Short introduction of an expert in the field setting the stage - **E. Menu**

The myeloma microenvironment in drug resistance - **E. Menu**

How to overcome microenvironment induced drug resistance and novel agents in heavily pre-treated patients - **E. Ocio**

19.15-19.30 CONCLUSION & FINAL GREETINGS

Enjoy the virtual experience!

SCIENTIFIC BOARD

Mario Boccadoro (Italy)
Hermann Einsele (Germany)
Maria-Victoria Mateos (Spain)
Philippe Moreau (France)
Pieter Sonneveld (The Netherlands)

SCIENTIFIC PROGRAM COORDINATORS

Pieter Sonneveld (The Netherlands)
Sonja Zweegman (The Netherlands)

SCIENTIFIC SECRETARIAT

Francesca Gay (Italy)
Niels van de Donk (The Netherlands)

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via De' Poeti, 1/7 - 40124 Bologna - Italy
Ph +39 051 4210559
Fax +39 051 4210174
E-mail: emnmeeting@ercongressi.it
www.ercongressi.it

2nd Meeting
European Myeloma Network
Virtual | March 3-6, 2021